NRT study debated
This article was originally published in The Tan Sheet
Conclusions that nicotine replacement therapy has not increased smoking cessation rates since it switched OTC "have the potential to damage public confidence in NRT and may deter smokers from using effective treatment," according to a letter in Dec. 25 JAMA. Commenting on a recent study in the journal, Mikael Franzon, PhD, et al., Pharmacia, maintain the trial was "nonrandomized, noncontrolled" and "limited by retrospective self-reporting" of study participants (1"The Tan Sheet" Sept. 16, 2002, p. 11). Lindsay Stead, University of Oxford, et al., echo these assertions, noting it is "premature to draw inferences" from findings derived from self-reported data in a single state (California). In reply, study author John Pierce, PhD, UC-San Diego, says that falsely raising smokers' expectations about NRT without providing an "adequate explanation of the limitations...may be counterproductive in the long-term"...
You may also be interested in...
Recently published data indicating nicotine replacement therapy efficacy has diminished over the years with OTC availability is at odds with "authoritative reviews and conclusions" supporting the use of such products, GlaxoSmithKline maintained
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.